Gero Kramer
A5071435826- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- Prostate Cancer Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Cancer Immunotherapy and Biomarkers
- Hormonal and reproductive studies
- Renal cell carcinoma treatment
- Diabetes Management and Research
- PARP inhibition in cancer therapy
- Bladder and Urothelial Cancer Treatments
- Kidney Stones and Urolithiasis Treatments
- Peptidase Inhibition and Analysis
- Renal and related cancers
- Cancer Genomics and Diagnostics
- Urinary Bladder and Prostate Research
- Diabetes and associated disorders
- Medical Imaging Techniques and Applications
- Pediatric Urology and Nephrology Studies
- Bone health and treatments
- Health and Medical Studies
- Immunotherapy and Immune Responses
- Inflammatory Biomarkers in Disease Prognosis
- Radiomics and Machine Learning in Medical Imaging
- Diabetes Treatment and Management
- Immune Cell Function and Interaction
Medical University of Vienna
2016-2025
Vienna General Hospital
2000-2024
Comprehensive Cancer Center Vienna
2014-2024
Institut Bergonié
2024
Arbeitsgemeinschaft für Klinische Ernährung
2014-2023
University Clinic of Traumatology
2020-2021
Université Paris-Sud
2019
Cornell University
2019
Donauspital
2017
Kantonsspital Graubünden
2014
In advanced prostate cancer (APC), successful drug development as well advances in imaging and molecular characterisation have resulted multiple areas where there is lack of evidence or low level evidence. The Advanced Prostate Cancer Consensus Conference (APCCC) 2017 addressed some these topics. To present the report APCCC 2017. Ten important controversy APC management were identified: high-risk localised locally cancer; “oligometastatic” castration-naïve castration-resistant role APC;...
The efficacy and safety of cabazitaxel, as compared with an androgen-signaling–targeted inhibitor (abiraterone or enzalutamide), in patients metastatic castration-resistant prostate cancer who were previously treated docetaxel had progression within 12 months while receiving the alternative enzalutamide) are unclear.
Innovations in imaging and molecular characterisation the evolution of new therapies have improved outcomes advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety clinical topics that greatly impact daily practice. To supplement evidence-based guidelines, 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) surveyed experts about key dilemmas management.To present consensus voting results for select questions from APCCC 2022.Before conference,...
There is an unmet need for therapeutic options that prolong survival patients with heavily pretreated, metastatic castration-resistant prostate cancer (mCRPC). The phase III, open-label KEYLYNK-010 study evaluated pembrolizumab plus olaparib versus a next-generation hormonal agent (NHA) biomarker-unselected, previously treated mCRPC.
Innovations have improved outcomes in advanced prostate cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that greatly impact daily practice. The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) surveyed experts key questions clinical management order supplement evidence-based guidelines. Here present voting results for from APCCC 2024.
The aim of this study was to assess whether low serum testosterone levels in men with newly diagnosed prostate cancer have an association the endocrine status, prostate-specific antigen (PSA) levels, Gleason score, and androgen receptor expression.Besides a full clinical work-up, following hormones were quantified by analysis: total testosterone, human luteinising hormone (hLH), follicle stimulating (hFSH), estradiol, dehydroepiandrostendione (DHEA). In subgroup men, expression determined...
Abstract Cytokeratins are released from carcinoma cells by unclear mechanisms and commonly used serum tumor markers (TPA, TPS, CYFRA 21–1). We here report that soluble cytokeratin-18 (CK18) is human during cell death. During necrosis, the cytosolic pool of CK18 was released, whereas apoptosis associated with significant release caspase-cleaved fragments. These results suggested assessments different forms in patient sera could be to examine death modes. Therefore, measured local venous blood...
Abstract BACKGROUND Benign prostatic hyperplasia (BPH) frequently exhibit infiltration of CD4 + /CD45RO memory‐T‐lymphocytes. Expression and impact lymphocyte‐derived growth factors on stromal cell (PSC) were investigated. METHODS Lymphokine synthesis in normal prostate tissues (n = 3), BPH‐tissues 13), BPH‐derived T‐cells 6), epithelial cells (BPH‐EC) 5), prostate‐derived 3) lines (BPH‐SC) cancer (CaP) was analyzed by RT‐PCR Southern‐blotting. The effect interleukin (IL)‐2, ‐4, ‐7,...
Abstract BACKGROUND: Sunitinib and sorafenib are tyrosine kinase inhibitors that have important antitumor activity in metastatic renal cell carcinoma (mRCC). Hypothyroidism constitutes a commonly reported side effect of both drugs, particularly sunitinib. The objective this analysis was to investigate whether the occurrence hypothyroidism during treatment with sunitinib affects outcome patients mRCC. METHODS: Eighty‐seven consecutive mRCC who were receive or included prospective analysis....
This review covers recent developments in the role of chronic inflammation pathogenesis and progression benign prostatic hyperplasia (BPH).A paper on subanalysis Medical Therapy Prostate Symptoms study highlighted BPH as determined by pathological tissue obtained 4.5-year study. It shows patients with had significantly larger prostates, higher serum prostate specific antigen a greater risk urinary retention. follows several other in-situ studies which demonstrated that elevated expression...
Primary staging of prostate cancer relies on modalities, which are limited. We evaluate simultaneous [68Ga]Ga-PSMA-11 PET (PSMA-PET)/MRI as a new diagnostic method for primary tumor-node-metastasis compared with histology and its impact therapeutic decisions.We investigated 122 patients PSMA-PET/MRI prior to planned radical prostatectomy (RP). endpoint was the accuracy in tumor staging-relevant histology. In addition, multidisciplinary team reassessed initial approach management.PSMA-PET/MRI...
The first aim of this study was to evaluate 68Ga-PSMAHBED-CC conjugate 11 positron emission tomography (PSMA PET) parameters for assessment response 177Lu-PSMA-617 radioligand therapy (RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC). second investigate factors associated overall survival (OS). We retrospectively assessed mean standardized uptake values (SUVmean) and total tumor volumes (TTV) on PSMA PET 38 55 mCRPC before after RLT. PSA testing PET/CT(MRI)...
Abstract Purpose Risk classification of primary prostate cancer in clinical routine is mainly based on prostate-specific antigen (PSA) levels, Gleason scores from biopsy samples, and tumor-nodes-metastasis (TNM) staging. This study aimed to investigate the diagnostic performance positron emission tomography/magnetic resonance imaging (PET/MRI) vivo models for predicting low-vs-high lesion risk (LH) as well biochemical recurrence (BCR) overall patient (OPR) with machine learning. Methods...
BRCA1 and, more commonly, BRCA2 mutations are associated with increased risk of male breast cancer (MBC). However, only a paucity data exists on the pathology cancers (BCs) in men BRCA1/2 mutations. Using largest available dataset, we determined whether MBCs arising mutation carriers display specific pathologic features and these differ from those female BCs (FBCs). We characterised 419 using logistic regression analysis, contrasted 9675 FBCs population-based 6351 Surveillance, Epidemiology,...
To evaluate the diagnostic performance of [68Ga]Ga-PSMAHBED-CC conjugate 11 positron emission tomography (PSMA-PET) in early detection metastases patients with biochemical recurrence (BCR) after radical prostatectomy (RP) for clinically non-metastatic prostate cancer, to compare it CT/MRI alone and assess its impact on further therapeutic decisions. We retrospectively assessed 117 consecutive hormone-naïve BCR who had 68Ga-PSMA PET/CT (n = 46) or PET/MRI 71) between May 2014 January 2017....
19 Background: Docetaxel is a treatment option following disease progression on next-generation hormonal agent (NHA) for patients with mCRPC, but there an urgent need more efficacious treatments. The randomized, double-blind, phase 3 KEYNOTE-921 study (NCT03834506) evaluated the efficacy and safety of pembrolizumab + docetaxel vs placebo participants (pts) mCRPC who had received prior NHA therapy. Methods: Eligible pts were ≥18 years old, that progressed androgen deprivation therapy, 1 NHA,...
Abstract Background To validate the clinical utility of a previously identified circulating tumor DNA methylation marker (meth-ctDNA) panel for disease detection and survival outcomes, meth-ctDNA markers were compared to PSA levels PSMA PET/CT findings in men with different stages prostate cancer (PCa). Methods 122 PCa patients who underwent [⁶⁸Ga]Ga-PSMA-11 plasma sampling (03/2019–08/2021) analyzed. cfDNA was extracted, 8 individual queried. PET scans qualitatively quantitatively assessed....
<b><i>Objective:</i></b> To describe the phenotypic spectrum and genetics of periventricular nodular heterotopia (PNH) caused by <i>FLN1</i> mutations in four men. <b><i>Background:</i></b> X-linked PNH (MIM #300049) implies prenatal or early postnatal lethality boys 50% recurrence risk daughters affected women. <b><i>Methods:</i></b> Clinical examination, cognitive testing, MRI, mutation analysis (denaturing high-performance liquid chromatography direct sequencing) on blood lymphocytes...
Multipotent mesenchymal stromal cells (MSCs) are found in a variety of adult tissues including human dermis. These MSCs morphologically similar to bone marrow–derived MSCs, but unclear phenotype. To shed light on the characteristics dermal this study was designed identify and isolate by specific marker expression profile, subsequently rate their differentiation potential. Immunohistochemical staining showed that MSC markers CD73/CD90/CD105, as well CD271 SSEA-4, expressed situ. Flow...